A Clinical Trial of Patients With Melanoma

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT02915666
Phase
PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Digoxin Combination — DRUG
    Digoxin 0.25 mg PO daily will be given for 8-week cycles
  • Dabrafenib — DRUG
    dabrafenib 150mg PO twice daily for 8-week cycles
  • Trametinib — DRUG
    trametinib 2 mg PO daily for 8-week cycles

Study Details

This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.

Key Dates

Start date
Oct 31, 2016
Status verified
May 2018
Primary completion
Jul 17, 2017
Completion
Jul 17, 2017

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Digoxin combination for Melanoma
    Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.

Primary Outcome Measure

Frequency of DLTs [ Time Frame: Every 3 weeks for 36 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75063-

Find similar trials in Dallas, TX

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies